DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer
Retrieved on:
Tuesday, September 14, 2021
Immunotherapy, DNX-2401, Emory University, Cancer, Drug discovery, Virology, DIPG, University, Research and development, Diffuse intrinsic pontine glioma, Mercury, Patient, Molecular genetics, Glioblastoma, Doctor of Philosophy, Cell biology, Colorectal cancer, Mass flow (life sciences), Fast track (FDA), Acquisition, Time, Liver disease, Chicago (franchise), Pharmaceutical industry
"We are thrilled to welcome Dave to the executive leadership team at DNAtrix," said Jeffrey Knapp, chief executive officer of DNAtrix. "Dave has expertise in developing products that elicit immune responses against targets of interest through various therapeutic modalities, including viral-based vaccines. His deep experience leading oncology drug development programs for innovative, young, as well as established biopharmaceutical companies -- such as Amgen -- will prove invaluable as we advance our pipeline with multiple product candidates being studied in several tumor types and two programs in pivotal stage development."
Key Points:
- "We are thrilled to welcome Dave to the executive leadership team at DNAtrix," said Jeffrey Knapp, chief executive officer of DNAtrix.
- "Dave has expertise in developing products that elicit immune responses against targets of interest through various therapeutic modalities, including viral-based vaccines.
- Prior to joining DNAtrix, Dr. Liebowitz was most recently vice president of Clinical Oncology at Xencor, Inc. From 2012 to 2018, he served as the chief medical officer for Vaxart, Inc., a novel vaccine development company.
- He was previously the Chief Scientific and Medical Officer for Vivaldi Biosciences, an influenza vaccine and therapeutics biotechnology company.